Short interest for CervoMed gives investors a sense of the degree to which investors are betting on the decline of CervoMed's stock. Short interest data is updated every two weeks.

CervoMed Stock (NASDAQ:CRVO), Short Interest Report

CervoMed

CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

News

Health Care

Markets

Trading Ideas

General

CRVO

By David Bautz, PhD

Business Update

Biomarker Data Presented at AD/PD 2024

CRVO: $150 Million Financing Strengthens Balance Sheet; Topline Data for Phase 2b Trial in 4Q24

Price Target

Small Cap

Pre-Market Outlook

Analyst Ratings

HBAN

PLOW

PRGO

SMPL

SWAV

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Disney To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday

CervoMed Inc

Serve Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) reported quarterly losses of $(0.37) per share. This is a 51.95 percent increase over losses of $(0.77) per share from the same period last year. The company reported $946.71 thousand in sales this quarter. This is a 2.25K percent increase over sales of $40.25 thousand the same period last year.

Earnings

SERV

Serve Robotics Q1 EPS $(0.37) Up From $(0.77) YoY, Sales $946.71K Up From $40.25K YoY

<a href="https://www.bloomberg.com/news/articles/2024-05-15/sumitomo-mitsui-forecasts-profit-will-rise-10-this-fiscal-year" title="https://www.bloomberg.com/news/articles/2024-05-15/sumitomo-mitsui-forecasts-profit-will-rise-10-this-fiscal-year">https://www.bloomberg.com/news/articles/2024-05-15/sumitomo-mitsui-forecasts-profit-will-rise-10-this-fiscal-year</a>
<a href="https://www.bloomberg.com/news/articles/2024-05-15/sumitomo-mitsui-forecasts-profit-will-rise-10-this-fiscal-year" title="https://www.bloomberg.com/news/articles/2024-05-15/sumitomo-mitsui-forecasts-profit-will-rise-10-this-fiscal-year">https://www.bloomberg.com/news/articles/2024-05-15/sumitomo-mitsui-forecasts-profit-will-rise-10-this-fiscal-year</a>

Bloomberg Earlier Reported 'Japan's Biggest Banks Forecast Record Profits As Rates Rise'

Alerus Financial Corporation ("Alerus") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRS#NASDAQ">ALRS</a>) and HMN Financial, Inc. ("HMNF") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HMNF#NASDAQ">HMNF</a>) jointly announced today the signing of a definitive Agreement and Plan of Merger (the "Merger Agreement") pursuant to which Alerus will acquire, in an all-stock merger, HMNF, a savings and loan holding company headquartered in Rochester, Minnesota, and the parent company of Home Federal Savings Bank ("Home Federal"). Under the terms of the Merger Agreement, HMNF will merge with and into Alerus (the "Merger") and Home Federal will merge with and into Alerus' wholly-owned bank subsidiary, Alerus Financial, National Association, in a transaction valued at approximately $116.4 million.
This press release features multimedia. View the full release here: <a href="https://www.businesswire.com/news/home/20240515095446/en/">https://www.businesswire.com/news/home/20240515095446/en/</a>
The Merger represents the twenty-sixth acquisition for Alerus since 2000 as part of its long-term plan to continually expand its business segments, including banking, wealth services, and retirement and benefits plans and services. Upon completion of the Merger, the combined company will have approximately $5.5 billion in total assets, $3.7 billion in total loans and $4.3 billion in total deposits, assets under administration and management of approximately $43.1 billion, with 29 locations across the Midwest, as well as Arizona.

ALRS

HMNF

Alerus Financial To Acquire HMN Financial In A Transaction Valued At ~$116.4M

Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) is expected to release earnings results for its first quarter, before the <a href="https://www.benzinga.com/quote/WMT/earnings">opening bell on Thursday</a>.
Analysts expect the Bentonville, Arkansas-based company to report quarterly earnings at 52 cents per share, up from 49 cents per share in the year-ago period. Walmart is projected to post revenue of $159.52 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Walmart is reportedly set to lay off hundreds of corporate employees and relocate others to its <a href="https://www.benzinga.com/markets/equities/24/05/38809328/walmart-to-cut-hundreds-of-corporate-jobs-relocate-workers-to-central-hubs">main corporate hubs</a>.
With the recent buzz around Walmart, some investors may be eyeing potential gains from the company's dividends too. As of now, Walmart offers an annual dividend yield of 1.39%, which is a quarterly dividend amount of 20.75 cents per share (83 cents a year).
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $432,728 or around 7,229 shares. For a more modest $100 per month or $1,200 per year, you would need $86,558 or around 1,446 shares.
Read This: <a href="https://www.benzinga.com/news/earnings/24/05/38835371/cisco-prestige-consumer-healthcare-and-3-stocks-to-watch-heading-into-wednesday">Cisco, Prestige Consumer Healthcare And 3 Stocks To Watch Heading Into Wednesday</a>
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($0.83 in this case). So, $6,000 / $0.83 = 7,229 &nbsp;($500 per month), and $1,200 / $0.83 = 1,446 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
WMT Price Action: Shares of Walmart fell 0.9% to close at $59.86 on Tuesday.
Read More: <a href="https://www.benzinga.com/news/24/05/38817342/jim-cramer-says-nu-skin-is-overvalued-praises-fabulous-pure-storage">Jim Cramer Says Nu Skin Is &#8216;Overvalued,&#8217; Praises &#8216;Fabulous&#8217; Pure Storage</a>
Photo: Shutterstock

Long Ideas

Dividends

How To Earn $500 A Month From Walmart Stock Ahead Of Q1 Earnings

<ul>
<li>Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) today announced the results from its second Phase III study of tradipitant in motion sickness, confirming the previously reported results of two efficacy studies demonstrating that tradipitant is effective in the prevention of vomiting associated with motion sickness. This Phase III study was conducted in real-world conditions on boats in the coastal waters of the United States (U.S.).</li>
</ul>

VNDA

Vanda Pharmaceuticals Announces Positive Results From Second Phase III Study Of Tradipitant, Confirming Efficacy In Preventing Motion Sickness-Related Vomiting

BMO Capital analyst Michael Markidis maintains FLAGSHIP CMNTYS REAL ESTATE INVT TR (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MHC#TSX">MHC</a>) with a Outperform and lowers the price target from C$19 to C$18.5.

TSX:MHC

BMO Capital Maintains Outperform on FLAGSHIP CMNTYS REAL ESTATE INVT TR, Lowers Price Target to C$18.5

Barclays analyst Jeffrey Bernstein maintains Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Equal-Weight and lowers the price target from $80 to $60.

JACK

Barclays Maintains Equal-Weight on Jack In The Box, Lowers Price Target to $60

Twin Vee PowerCats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) reported quarterly losses of $(0.18) per share. This is a 5.26 percent increase over losses of $(0.19) per share from the same period last year. The company reported $5.28 million in sales this quarter. This is a 40.57 percent decrease over sales of $8.88 million the same period last year.

VEEE

Twin Vee PowerCats Q1 EPS $(0.18) Up From $(0.19) YoY, Sales $5.28M Down From $8.88M YoY

Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) reported quarterly losses of $(2.19) per share which missed the analyst consensus estimate of $(0.35) by 525.71 percent. This is a 20.36 percent increase over losses of $(2.75) per share from the same period last year.

Earnings Misses

ADIL

Adial Pharmaceuticals Q1 EPS $(2.19) Misses $(0.35) Estimate

Biotech

IMNN

Imunon Abstract On Phase 2 Study With IMNN-001 Plus Bevacizumab Accepted For Presentation At ASCO Annual Meeting

First Quarter 2024 Highlights vs. Same Year-Ago Quarter
<ul>
<li>Revenue in the first quarter of 2024 increased significantly to $11.4 million compared to approximately $198.9K for the same period in 2023. The increase was driven to the Company's pivot to selling freeze dried candy in the prior year period, as well as the growing market for freeze dried candy. The increase also reflects the benefits of the Company's expanded production capacity. &nbsp;</li>
<li>Gross profit in the first quarter of 2024 increased significantly to $4.6 million compared to approximately $114.9K for the same period in 2023. Gross margin was 40.6% compared to 57.8% in the prior-year period. Relative to the prior-year period, gross margin in the first quarter of 2024 reflects higher labor and production costs associated with the Company's increased scale. In order to meet growing demand, the Company expects to continue investing in its operations to increase production capacity, which is expected to constrain quarterly gross margins in the near term.&nbsp;&nbsp;</li>
<li>Operating expenses in the first quarter of 2024 were $3.7 million compared to $1.0 million for the same period in 2023. The increase was primarily driven by higher compensation and professional services expenses as we scaled up the business and invested in system and process improvements in anticipation of being listed on Nasdaq.&nbsp;&nbsp;</li>
<li>Net income in the first quarter of 2024 was approximately $510.6K compared to a net loss of $(1.4) million for the same period in 2023. The improvement reflects the higher level of gross profit generated during the quarter.</li>
<li>Adjusted EBITDA (a non-GAAP financial measure defined and reconciled herein) in the first quarter of 2024 improved to $2.45 million compared to approximately $171.3k for the same period in 2023.</li>
<li>Cash and cash equivalents were $6.8 million at March 31, 2024, compared to $2.4 million at December 31, 2023.&nbsp;The Company received $3.7 million in proceeds from the equity private placement completed in March of 2024.</li>
</ul>
For a reconciliation of Adjusted EBITDA to the nearest comparable GAAP metric, Net income, please see the tables below.

SOWG

Sow Good Q1 EPS $0.06 Up From $(0.29) YoY; Revenue $11.41M Up From $198,930 YoY

Barclays analyst Christine Cho maintains First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) with a Overweight and raises the price target from $227 to $228.

FSLR

Barclays Maintains Overweight on First Solar, Raises Price Target to $228

Chinese EV maker Nio Inc&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) new <a href="https://www.benzinga.com/news/24/05/38665741/teslas-chinese-rival-nio-partners-with-warren-buffett-backed-byd-to-launch-budget-friendly-ev-brand">sub-brand Onvo</a> will be headed by former Vice President of Marketing at Disney, Ai Tiecheng. Interestingly, the name of the new brand&#8217;s head means &#8220;will surely succeed.&#8221;
What Happened: Ai Tiecheng, who also goes by his English name Alan Ai, is the 107th owner of the Nio ES8 Founding Edition, CnEVPost <a href="https://cnevpost.com/2024/05/15/who-is-head-of-nio-onvo/">reported</a>, citing a post by Nio President Qin Lihong on Nio App. 
&#8220;We feel confident putting the Onvo brand in his hands,&#8221; Qin wrote. 
Back in 2015, Nio was working on putting together a user experience team and Ai was preparing for the opening of Disneyland in Shanghai. Ai subsequently joined Nio in January 2021 and began creating the team for Onvo, the report said.
Why It Matters: Nio held the Onvo brand launch on May 15, on the occasion of International Family Day. Onvo, unlike Nio, is expected to <a href="https://www.benzinga.com/markets/asia/24/05/38728220/chinese-ev-startup-nios-stock-jumps-premarket-amid-weak-stock-futures-whats-going-on">sell cheaper EVs aimed at the family market</a>. 
Nio, on the other hand, is focused on more luxury vehicles with an average transaction price of over 300,000 yuan.
Onvo&#8217;s first EV will be the L60 SUV designed by veteran automotive designer Raul Pires with experience designing several Bentley models. 
The vehicle is expected to compete against the Tesla Model Y which starts at 249,900 yuan ($34606.91) in the Chinese market, CnEVPost said. It is expected to be launched globally by<a href="https://www.benzinga.com/markets/equities/24/05/38662438/tesla-rival-nio-to-roll-out-mass-market-ev-brand-in-may-report"> the year-end. </a>
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:&nbsp;<a href="https://www.benzinga.com/markets/asia/24/05/38837883/teslas-top-rival-byd-reveals-starting-price-of-hybrid-electric-pickup-in-mexico-launch-yes-its-a-lot">Tesla&#8217;s Top Rival BYD Reveals Starting Price Of Hybrid Electric Pickup In Mexico Launch — Yes, It&#8217;s A Lot Cheaper Than The Cybertruck</a>
Photo courtesy: Nio

Asia

Tech

Nio's Mass-Market EV Brand Will Be Led By Former Disney Exec Whose Name Literally Means 'Will Surely Succeed'

BMO Capital analyst Joel Jackson maintains Arcadium Lithium (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTM#NYSE">ALTM</a>) with a Market Perform and lowers the price target from $6 to $5.5.

ALTM

BMO Capital Maintains Market Perform on Arcadium Lithium, Lowers Price Target to $5.5

Barclays analyst Pablo Monsivais maintains Azul (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) with a Equal-Weight and lowers the price target from $12 to $10.

AZUL

Barclays Maintains Equal-Weight on Azul, Lowers Price Target to $10

Safety Shot, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOT#NASDAQ">SHOT</a>) is thrilled to announce it will be introducing Safety Shot into 50 targeted 7-Elevens in Los Angeles in June. Safety Shot is the world&#39;s first rapid alcohol reducer by supporting its metabolism, offering a unique product which aligns perfectly with 7-Eleven&#39;s beer and alcohol shopper. Safety Shot will be partnering with the local franchisee stores to begin the process growing the brand, then scaling into the 300+ 7-Eleven locations across SoCal and building towards our goal of a national launch.

SHOT

Safety Shot Partnering With The Local Franchisee Stores, Then Scaling Into The 300+ 7-Eleven Locations Across SoCal And Building Towards Goal Of National Launch

BMO Capital analyst Randy Ollenberger maintains Strathcona Resources (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SCR#TSX">SCR</a>) with a Market Perform and raises the price target from C$33 to C$35.

TSX:SCR

BMO Capital Maintains Market Perform on Strathcona Resources, Raises Price Target to C$35

Barclays analyst Andrew Mok maintains Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Overweight and lowers the price target from $91 to $89.

ACHC

Barclays Maintains Overweight on Acadia Healthcare Co, Lowers Price Target to $89

– Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin
– Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models

MBRX

Moleculin Commences NIH-Funded Phase 2 Clinical Trial Of STAT3 Inhibitor For Glioblastoma

WISA

WiSA Technologies Secures Five WiSA E Licenses With Major Brands; Three Additional Global Brands Reviewing Agreement; First WiSA E-Enabled Products To Launch In Second Half Of 2024

CervoMed (CRVO) has issued an update. CervoMed Inc. has shared vital information about its business operations, clinical studies, and financial hea...

CervoMed Updates Investors on Clinical and Financial Health

CervoMed stock soars on $149.4M private placement financing

CervoMed (CRVO) has issued an announcement. CervoMed Inc. has engaged in a $50 million private placement deal, selling over 2.5 million units, each...

CervoMed's Strategic $50 Million Private Placement Deal

iBio, Mesoblast, Kodiak Sciences among healthcare movers

Cervomed Inc. (CRVO) has disclosed a new risk, in the Economy & Political Environment category. Cervomed Inc. faces considerable business risk due ...

Cervomed Inc. Braces for Impact: How Political Uncertainty and the Presidential Election Could Shake Up the Pharma Industry

CervoMed GAAP EPS of -$0.82 beats by $1.23, revenue of $7.14M beats by $3.09M

CervoMed: H2 2024 Data For DLB Program A Major Inflection Point

CervoMed (CRVO) has shared an update. CervoMed Inc. has released key insights about its business operations, clinical studies, and financial health...

CervoMed Shares Operational and Financial Insights Online

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inventiva (IVA – Research Report), CervoMed (CRVO – ...

Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), CervoMed (CRVO) and Teladoc (TDOC)

CervoMed (CRVO) has provided an announcement. CervoMed Inc. has made key details about its business, clinical studies, and financial health availab...

CervoMed Updates Stakeholders on Clinical and Financial Status

AVTX

BYSI

IBIO

MESO

PAVM

SERA

TDOC

Press Releases

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board

CervoMed to Participate in the BIO CEO and Investor Conference

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

-

-

-

-

-

-

-

-

-

-

-

-

-

-

CervoMed Stock (NASDAQ:CRVO), Short Interest Report

People Also Watch